Eurazeo raises over €1bn for Eurazeo PME IV Fund

Jul 20, 2022 | News | 0 comments

Eurazeo has exceeded its fundraising target for the Eurazeo PME IV Fund by attracting more than €1bn, 50% more than its previous fund.

Since 2006, the small-mid buyout strategy’s assets under management have grown from €50 million to more than €1 billion. In 2011, these investments were financed solely by Eurazeo’s balance sheet, but now more than 60% of assets come from institutional and private investors, as opposed to 38% for the predecessor fund.

Partner-investors include top-tier institutional investors – asset managers, sovereign funds and insurance companies – and family offices originating in France (64%), other European countries (24%) and Asia (12%).

Their renewed confidence also reflects the returns generated by Eurazeo’s small-mid buyout strategy, resulting in particular from its strong track record in terms of exits. Recent disposals include Orolia (x3.7), Vitaprotech (x3.2) and Intech Médical (x3).

The fund has already got off to an strong start, investing 40% of its assets in five new investments: i-Tracing, an independent French leader in cybersecurity services; Dilitrust, a provider of unified, secure legal SaaS solutions; Wiismile, a provider of all-in-one employee benefit plans; Sevetys , a group of veterinary clinics; and Groupe Premium, a French distributor of life insurance and retirement savings solutions.

Get the week’s top news delivered directly to your inbox – Sign up for our newsletter

Sign up

“We are thrilled to officially welcome OPEN Health to the Astorg family and look forward to working with Rob and his talented team in continuing to build a global leader in the medical affairs and market access space,” said Judith Charpentier, Partner and Head of Healthcare at Astorg. “OPEN Health’s industry-leading expertise is only becoming more important for today’s pharmaceutical products, and we see a number of opportunities to further support the company’s diverse and growing customer base.”

“Our investment in OPEN Health embodies Amulet’s comprehensive value creation approach: we partner with exceptional management teams to build industry-leading businesses in the most attractive subsectors of healthcare,” said Ramsey Frank, President and Managing Partner of Amulet. “We are pleased to complete this transaction and are confident OPEN Health will continue to experience continued growth and success in partnership with Astorg.”

Astorg is a European private equity firm with over €17 billion of assets under management. Astorg works with entrepreneurs and management teams to acquire market leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance and capital they need to achieve their growth plans.

Enjoying a distinct entrepreneurial culture, a long-term shareholder perspective and a lean decision-making body, Astorg has valuable industry expertise in healthcare, software, technology, business services and technology-based industrial companies. Astorg has offices in London, Paris, New York, Frankfurt, Milan and Luxembourg.

Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million.  

Source: Businesswire

Can’t stop reading? Read more